Michele Stone, Ph.D., Director of Vaccines at Liquidia Technologies, has over ten years of industrial experience in vaccine development and molecular diagnostics. Dr. Stone obtained her Ph.D. from the University of Maryland, Baltimore in the field of Biochemistry/Molecular. Her Ph.D. thesis focused on further defining natural genetic transformation in Haemophilus influenza, and her postdoctoral work pertained to the field of Physiology, specifically Muscular Dystrophy. She began her industrial career at Aeras working toward the development of TB vaccines. After several years, she transitioned her focus to the field of molecular diagnostics at Canon US Life Sciences. Her contributions aided in the development of a novel PCR device that will revolutionize the field of molecular diagnostics and personalized medicine. Dr. Stone’s passion for TB vaccine development prompted her to return to Aeras, where she continued to lead efforts in the development of new TB vaccine candidates. While at Aeras, Dr. Stone was responsible for viral, protein, DNA, and RNA platform vaccine development. These efforts included managing collaborations with various government, academic, and industrial partners. Several of these partnerships and collaborations have produced novel TB candidates that are in late pre-clinical/clinical development. Dr. Stone’s desire to advance novel vaccine development brought her to Liquidia. Liquidia is currently advancing vaccine development through the use of PRINT (particle replication in non-wetting templates) technology. PRINT is a novel nanoparticle platform providing compositional flexibility with the ability to specify size and shape in formulating vaccines. At Liquidia, Dr. Stone is responsible for advancing the pre-clinical development of novel vaccine targets utilizing PRINT technology. Her role includes the management of various industrial, academic, and non-profit partnerships. The outcome of these collaborations indicates that PRINT technology may provide specific advantages over current vaccine platforms.
back to speakers